A prospective randomized multicenter open-label phase 3 trial of extending aromatase-inhibitor adjuvant therapy to 10 years – Results from 1697 postmenopausal women in the N-SAS BC05 trial: Arimidex extended adjuvant randomized study (AERAS). Oral presentation at: 2018 San Antonio Breast Cancer Symposium; December 4 – 8, 2018. San Antonio, TX; Abstr. GS3-04 - Ohtani, S; Iijima, K; Higaki, K